dose of prednisone required was 40 mg/d (range, 5-90 mg/d) ( Table 1) . Disease activity was controlled 2 weeks after raising the prednisone dose in 41% of patients (n=12) and after 3 weeks in 62% (n=18) (data not shown). The end of the consolidation phase was reached after a median of 4 weeks from treatment of the flare (range, 1-17 weeks). The prednisone dose could be reduced by 50% of the maximum level required to control disease activity after a median of 7 weeks from the start of treatment (range, 1-30 weeks). After 4 months, 38% of patients achieved partial remission (no lesions for Ն1 month with Ͻ15 mg/d of prednisone) (n=14); after 9 months, 62% (n=18) (data not shown). Complete remission (no lesions for Ն1 month with no systemic treatment) was achieved in 24% of patients at 11 months (n=7).
The prednisone dose required to control disease activity and the kinetics of response were related to the baseline dose of prednisone at the time the flare occurred ( Table 2) . A median maximum prednisone dose of 20 mg/d was required to control disease activity in patients whose disease flared while they were not undergoing treatment with systemic steroids, while 45 mg/d was required for those on a prednisone regimen of 10 mg/d or higher. At 11 months, complete remission was induced in 36% (n=4) and 0% of the 2 groups, respectively. Patients who were not undergoing systemic therapy prior to a flare reached the end of the consolidation phase and had a 50% decrease in their maximum prednisone dose a median of 2 weeks earlier in each case than those on a prednisone regimen greater than 10 mg/d (data not shown). There was 1 grade 2 (localized infection) and no grade 3 toxic effects during this 11-month period. Comment. These results indicate that flares in the activity of pemphigus vulgaris respond rapidly to conventional treatment with systemic steroids. Flares in disease activity were controlled a median of 3 weeks after increasing the steroid dose. After a median of 4 weeks, the ste- a At 11 months, 76% of patients had experienced partial remission (n=22), and 24% had experienced complete remission (n=7). roid dose began to be tapered, and after 7 weeks, the dose could be tapered to half the maximum dose. The rate of complete remission was 24% at 11 months (n=7). This is consistent with a prior study, which found that complete remission occurred in 25%, 50%, and 75% of patients at 2, 5, and 10 years, respectively, following diagnosis. 1 Partial remission was 76% at 11 months (n=22), similar to a 71% remission rate after treatment with mycophenolate and prednisone after 13 months. 4 Patients receiving a lower baseline dose of systemic steroids required less prednisone (lower maximum dose and increased rate of taper) and were more likely to achieve complete remission than those taking a higher baseline dose. These results suggest that the kinetics of response to treatment is related to the baseline dose of medication and that this variable needs to be considered when judging response to new therapies. Furthermore, these results provide a benchmark against which the results of newer therapies can be evaluated. 
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C
haperonin 10 is a highly conserved protein that is essential in protein folding. Recombinant chaperonin 10 (Cpn10) (1 amino acid different to native chaperonin 10) and has immunomodulatory function in vitro and in vivo.
1,2 Treatment with Cpn10 improved clinical disease activity in patients with rheumatoid arthritis and downregulated cytokine responses of immune cells to cellular stimuli. 2 An exploratory study of Cpn10 treatment for chronic plaque psoriasis is reported.
Methods. Forty patients were screened, and 24 (aged 18 to 75 years) with plaque psoriasis for at least 6 months prior to screening, 10% or greater of the body surface area affected by plaque psoriasis, a Psoriasis Area and Severity Index (PASI) score of 12 or higher (severe psoriasis), and a Physician's Global Assessment (PGA) score of at least moderate at screening despite current therapies were selected. Patients taking psoriasis medications were eligible if the regimen they had been following was a stable systemic dose for 28 days or longer prior to treatment with Cpn10 or 14 days or longer with topical dosing. Exclusion criteria were infections, malignant neoplasms, abnormal hematology, renal, or liver function test findings, and treatment with any anti-tumor necrosis factor ␣ (TNF-␣) agents or immunosuppressive drugs within 28 days of starting Cpn10 treatment. In this singlecenter, double-blind study, patients were randomized into 5-, 7.5-, and 10-mg treatment groups of Cpn10 (XToll; CBio Limited, Brisbane, Australia) that was given intravenously twice weekly for 12 weeks. Outcomes were PASI and PGA scores and the percentages of patients with at least a 50%, 75%, or 90% improvement in PASI scores (PASI 50, PASI 75, and PASI 90). In vitro peripheral blood mononuclear cell reactivity to lipopolysaccharide stimulation was measured by cytokine production. Safety was assessed by physical examination, adverse event profile, laboratory parameters, and vital signs. Table; Figure, C). A PASI 90 was observed in one patient in the 7.5-mg group on days 56 and 70 and in another patient in the 10-mg group on day 70. No difference was seen in between the dose groups at day 84 in the percentage of patients exhibiting a PASI 75 response (P=.08). Peripheral blood mononuclear cells isolated from patients after treatment with Cpn10 produced significantly less TNF-␣ (day 28, P=.046; day 56, P = .04) (baseline median, 1397 pg/mL) and interleukin 1␤ (day 28, P=.046; day 56, P=.03) (baseline median, 2567 pg/mL) in the 10-mg group (Figure, D) . The most common adverse event was exacerbation of psoriasis (4 cases during the study and 3 cases after the final dose). Decreased lymphocyte counts were observed in 6 patients, 2 of whom had upper respiratory tract infections. One patient was lymphopenic at screening, possibly associated with concomitant sarcoidosis. One patient with diabetes mellitus experienced loss of consciousness judged to be unrelated to the study drug. Three adverse events were rated as probably treatment related (scotoma, psoriasis flare, increased proteinuria). Four patients showed a 4-fold increase in antibody titer to Cpn10. The rel- 
